Abstract Library

#1212 Circulating Gene Transcript Analysis of Pancreatic NETs

Introduction: PNETs are aggressive with poor survival. Therapeutic agents are available but efficacy determination is limited by imaging insensitivity and the lack of effective blood biomarkers.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Kidd M

Authors: Kidd M, Modlin I, Drozdov I, Alaimo D, Callahan S,

Keywords: PNET, NETest, PCR,

#1195 Neuroendocrine Gene Transcript Analysis of Blood Identifies Stable or Progressive NET Disease Treated with Somatostatin Analogs.

Introduction: An issue in NET management is defining stable or progressive disease and effective treatment. An alternative to RECIST criteria is a sensitive, reproducible blood biomarker test. Somatostatin analogs (SSA) are a chief therapy but efficacy is subjective and based on symptom control and imaging.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Alaimo D, Callahan S, Lepensky C, Jonzzon S, Teixeira N,

Keywords: Biomarker, SSA,

#913 A PCR-Based Multigene Transcript Analysis Blood Test Outperforms Chromogranin A in the Detection of Gastrointestinal and Pancreatic Neuroendocrine Tumors and is Unaffected by PPI Use or Hypertension

Introduction: A critical requirement in the management of gut NETs is a blood biomarker test that is sensitive, specific and reproducible.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Drozdov I, Aslanian H, Alaimo D,

Keywords: biomarker, CgA, NET, PCR,

#897 A Molecular Multi-Transcript Gene Blood Signature Significantly Outperforms Chromogranin A (CgA) in the Detection of Gut Neuroendocrine Tumors (NETs)

Introduction: A key issue in NET management is the need for a specific and sensitive biomarker to detect disease and assess treatment. CgA is widely utilized but has limitations.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Modlin I

Authors: Modlin I, Kidd M, Drozdov I, Alaimo D, Callahan S,

Keywords: biomarker, CgA, NET, PCR,

#344 Cell Cycle Phase Expression Profile Guided Selection of Proliferative Markers for Well-differentiated Small Intestinal Neuroendocrine Neoplasms

Introduction: Grading of neuroendocrine lesions is often determined by Ki-67 (immunostain), despite limited prognostic ability for this cell cycle marker in well-differentiated tumors (WDNETs) and carcinomas.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Lawrence B, Kidd M, Alaimo D, Svejda B, Drozdov I,

Keywords: biomarker, Ki-67, NALP1, neuroendocrine tumor, PCR, proliferation, survivin, transcript,